TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02857283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Participants will be exposed to a concentration of ozone for 6.5 hours at a concentration that varies 0.06 to 0.08

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Filtered Air
Description: Participants will be exposed to filtered clean air

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Filtered Air
Description: Participants will be exposed to filtered clean air

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Health and Exposure Tracker (HET)
Description: Ozone and heart rate tracker
Study: NCT01765751

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Cervical Distraction
Description: Manual Cervical Distraction (MCD) is a form of Low Velocity Variable Amplitude Spinal Manipulation (LVVA-SM). MCD procedure is performed with participant lying prone on a load instrumented table with moveable headpiece allowing guided head movement while recumbent. Clinician gently grasps posterior aspect of participant's neck with a broad contact (contact hand) between thumb and index finger at specific vertebral level. With opposite hand, clinician grasps control handle. Using contact hand, clinician exhibits superior traction to maintain a contact at a single vertebral level and ensuring a gentle movement via contact with control handle. Goal is to create a slow rhythmic (1-3 sec) localized distractive movement. In this trial, only axial distraction (Cox protocol 1) will be used.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Manual Cervical Distraction
Description: Manual Cervical Distraction (MCD) is a form of Low Velocity Variable Amplitude Spinal Manipulation (LVVA-SM). MCD procedure is performed with participant lying prone on a load instrumented table with moveable headpiece allowing guided head movement while recumbent. Clinician gently grasps posterior aspect of participant's neck with a broad contact (contact hand) between thumb and index finger at specific vertebral level. With opposite hand, clinician grasps control handle. Using contact hand, clinician exhibits superior traction to maintain a contact at a single vertebral level and ensuring a gentle movement via contact with control handle. Goal is to create a slow rhythmic (1-3 sec) localized distractive movement. In this trial, only axial distraction (Cox protocol 1) will be used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Cervical Distraction
Description: Manual Cervical Distraction (MCD) is a form of Low Velocity Variable Amplitude Spinal Manipulation (LVVA-SM). MCD procedure is performed with participant lying prone on a load instrumented table with moveable headpiece allowing guided head movement while recumbent. Clinician gently grasps posterior aspect of participant's neck with a broad contact (contact hand) between thumb and index finger at specific vertebral level. With opposite hand, clinician grasps control handle. Using contact hand, clinician exhibits superior traction to maintain a contact at a single vertebral level and ensuring a gentle movement via contact with control handle. Goal is to create a slow rhythmic (1-3 sec) localized distractive movement. In this trial, only axial distraction (Cox protocol 1) will be used.
Study: NCT02857283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Health and Exposure Tracker (HET)
Description: Ozone and heart rate tracker
Study: NCT01367561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Methylnaltrexone (MNTX)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02089243

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation therapy
Description: The adjustments in device parameters were performed, individually, and solely at the discretion of the primary epileptologist with a formal protocol guiding changes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resective surgery
Description: The experienced neurosurgery are responsible for the selection of surgical techniques employed for medically refractory medial temporal lobe epilepsy that provide an effective treatment with significant preservation of neurological function and acceptable surgical risks.
Study: NCT03755440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody (SHR-1210)
Description: PD-1 antibody (SHR-1210), 200mg, ivdrip, every 2 weeks.
Study: NCT03068468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB092
Description: BIIB092 intravenous infusion on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenous infusion on specified days
Study: NCT06749938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Holistic Intervention
Description: * Aerobic Exercise Prescription. Each participant will be given instruction on an exercise program to progress to perform a total of 150 minutes/wk of moderate-vigorous aerobic activity (including any yoga practice they choose to do) with two days of strengthening exercises using exercise bands.~* Yoga Protocol and Meditation Exercise. Participants will be asked to practice three 75-min session days per week. The program will focus on developing breath and body awareness/control (pranayama), focused concentration, meditation, muscular strength, muscular endurance, and mobility (flexibility) training that involves the mind body spirit connection.~* Diet Intervention. Coaching for diet modification will be incorporated into the psychosocial support messaging.~* Psychosocial Support. Motivational strategies to enhance exercise compliance comprise of electronic messaging using the BlueJay Mobile-Health, (Livermore, CA). This tele-health HIPPA compliant allows private communication.
Study: NCT04844957

Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin D
Description: Clinical Study

Intervention type: DEVICE
Group type: OTHER
Intervention: Full automatic chemiluminescence measuring instrument
Description: Chemiluminescence immunoassay
Study: NCT02915055

Intervention type: DRUG
Intervention: Ibuprofen 600 mg
Description: Ibuprofen 600 mg to be taken every 8 hours (TID) as needed (PRN

Intervention type: DRUG
Intervention: standard oxycodone/acetaminophen
Study: NCT00773435

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Echinacea purpurea 100 mg/ml in liquid formulation
Description: 10 ml BID for 10 consecutive days at the start of 3 consecutive 30 day periods

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 10 ml PO BID for 10 consecutive days at the beginning of 3 consecutive 30 day periods
Study: NCT03147456

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: (Cubitan Protein, Nutricia, Netherlands).
Description: Supplement contains (per 200 ml can) 20 g of protein, 250Kacl plus different micronutrient and macronutrient.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: (preOp, Nutricia, Netherlands).
Description: contains per can (200 ml), 0g protein, fat free, 100 kcal and enriched with electrolytes
Study: NCT02959957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temocillin
Description: Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial temocillin administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefotaxime
Description: Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial cefotaxime administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.
Study: NCT02108743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol.
Description: 2.5 mg of albuterol inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline placebo
Description: Placebo inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
Study: NCT04619914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt
Description: CLOMID (clomiphene citrate tablets USP) is an orally administered, nonsteroidal, ovulatory stimulant designated chemically as 2-\[p-(2-chloro-1,2-diphenylvinyl)phenoxy\] triethylamine citrate (1:1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole (Femara; Novartis pharma AG, Basle, Switzerland)
Description: Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Study: NCT01958541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Intervention I
Description: Insomnia-focused behavioral treatment (4 sessions).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Intervention II
Description: Insomnia-focused behavioral treatment (4 sessions).
Study: NCT00394069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0476, montelukast sodium
Description: Duration of Treatment: 14 Days
Study: NCT03935308

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MR guided Linear Accelerator
Description: The aim is to perform treatment planning to compute the highest feasible simultaneous boosting dose to the intraprostatic lesion while respecting normal tissue dose constraints. Patients will be treated with MR-guided localization and adaptive planning techniques.
Study: NCT00552149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemox, Cetuximab
Description: GEMOX (Arms 1 and 2), every two weeks:~Day 1: gemcitabine 1000 mg/m² intravenous (IV) infusion over 100 minutes (10 mg/m²/min) Day 2: oxaliplatin 100 mg/m² IV infusion over 2 h~Cetuximab (ErbituxÒ) (Arm B only) every two weeks:~(chemotherapy will be started one hour after the end of the cetuximab infusion).~Day 1 or Day 2: 500 mg/m² IV infusion over 150 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemox, Cetuximab
Description: GEMOX (Arms 1 and 2), every two weeks:~Day 1: gemcitabine 1000 mg/m² intravenous (IV) infusion over 100 minutes (10 mg/m²/min) Day 2: oxaliplatin 100 mg/m² IV infusion over 2 h~Cetuximab (ErbituxÒ) (Arm B only) every two weeks:~(chemotherapy will be started one hour after the end of the cetuximab infusion).~Day 1 or Day 2: 500 mg/m² IV infusion over 150 minutes
Study: NCT00577148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimonabant
Description: Tablet, oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Rimonabant)
Description: Tablet, oral administration
Study: NCT04083352

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pruvit Ketomax Ketone Salt
Description: 6-week supplementation with ketone salts

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was taken for 6-weeks and was calorie and flavor matched to the ketone salt supplement.
Study: NCT02759549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eSMART-MH
Description: eSMART-MH (Electronic Self-Management Resource Training for Mental Health) is a software, which is set in a 3-D virtual primary care office environment in which a subject interacts with avatar virtual healthcare staff (medical receptionist, medical assistant, providers, and a virtual healthcare coach). The avatars are programmed to behave like humans. The subject moves through the 3-D virtual primary care office and encounters virtual healthcare staff and providers. The subject practices discussing depressive symptoms with avatar healthcare providers and practices self-management skills related to symptoms of depression.The subject also interacts with the health care coach. The health care coach provides the subject with real-time strategies to enhance communication with healthcare providers during their virtual office visit. eSMART-MH will be used once a week throughout the duration of radiation treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Mood Tracking (Mood 24/7)
Description: Public social media data posted by participants will be accessed and downloaded to a computer program. Permission for the study team to access this data is optional.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Theater Testing Workshop
Description: The theater testing workshop consists of one to two one-on-one sessions with study staff during which participants will review a computer program for its content and usability, as well as discuss areas for improvement. Participants will also be asked to complete questionnaires and a attend a brief interview regarding any suggested improvements for the computer program.
Study: NCT01921543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITP Stimulation
Description: Model 7428 Kinetra® Neurostimulator~Model 3887 DBSTM Pisces Quad Compact Model 3389 DBSTM Brain Lead~Model 3387 DBSTM Brain Lead~Model 7482-51 Extension~Model 7482-66 Extension~Model 7482-95 Extension~Model 7436 AccessTM Therapy Controller~Model 3628 Dual Screener TM~Model 8840 N'Vision

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITP Stimulation
Description: Model 7428 Kinetra® Neurostimulator~Model 3887 DBSTM Pisces Quad Compact Model 3389 DBSTM Brain Lead~Model 3387 DBSTM Brain Lead~Model 7482-51 Extension~Model 7482-66 Extension~Model 7482-95 Extension~Model 7436 AccessTM Therapy Controller~Model 3628 Dual Screener TM~Model 8840 N'Vision

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CI/BNST stimulation
Description: Model 7428 Kinetra® Neurostimulator~Model 3887 DBSTM Pisces Quad Compact Model 3389 DBSTM Brain Lead~Model 3387 DBSTM Brain Lead~Model 7482-51 Extension~Model 7482-66 Extension~Model 7482-95 Extension~Model 7436 AccessTM Therapy Controller~Model 3628 Dual Screener TM~Model 8840 N'Vision

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CI/BNST stimulation
Description: Model 7428 Kinetra® Neurostimulator~Model 3887 DBSTM Pisces Quad Compact Model 3389 DBSTM Brain Lead~Model 3387 DBSTM Brain Lead~Model 7482-51 Extension~Model 7482-66 Extension~Model 7482-95 Extension~Model 7436 AccessTM Therapy Controller~Model 3628 Dual Screener TM~Model 8840 N'Vision

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CI/BNST stimulation
Description: Model 7428 Kinetra® Neurostimulator~Model 3887 DBSTM Pisces Quad Compact Model 3389 DBSTM Brain Lead~Model 3387 DBSTM Brain Lead~Model 7482-51 Extension~Model 7482-66 Extension~Model 7482-95 Extension~Model 7436 AccessTM Therapy Controller~Model 3628 Dual Screener TM~Model 8840 N'Vision

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No stimulation
Study: NCT04687553

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Simplified Evaluation of CONsciousness Disorders (SECONDs)
Description: All patients were assessed by the Simplified Evaluation of CONsciousness Disorders (SECONDs)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Simplified Evaluation of CONsciousness Disorders (SECONDs)
Description: All patients were assessed by the Simplified Evaluation of CONsciousness Disorders (SECONDs)
Study: NCT03552770

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: pro-re-nata repeated single or combined intra-vitreous injection of bevacizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: pro-re-nata repeated single or combined intra-vitreous injection of bevacizumab
Study: NCT03645850

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vismed gel Multi 0.3% eye drops
Description: Ophthalmic use. Vismed gel Multi 0.3% eye drops. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vismed Multi 0.18% eye drops
Description: Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
Study: NCT00738075

Intervention type: DEVICE
Intervention: Auditory cue
Description: When device recognizes automatically freezing episode it will generate auditory cue
Study: NCT02628093

Intervention type: DEVICE
Group type: OTHER
Intervention: THUNDERBEAT
Description: Tissue dissection and vessels ligation

Intervention type: DEVICE
Group type: OTHER
Intervention: LIGASURE
Description: Tissue dissection and vessels ligation
Study: NCT01897233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Study: NCT03749590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Patients receive 2 infusions (10 ml magnesium sulfate added to 500 ml NaCl 0.9%): the first infusion 60 min before and the second one 6 hours after ERCP

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NaCl 0,9%)
Description: Patients receive 2 infusions (10 ml NaCl 0.9% added to 500 ml NaCl 0.9%): the first infusion 60 min before and the second one 6 hours after ERCP
Study: NCT01315899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12471 30mg
Description: Given as a single dose once during the crossover study as per Williams design

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12471
Description: Given as a single dose once during the study as per Williams crossover design

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given once as a single dose during the study as per Williams crossover design
Study: NCT04157257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF tablet
Description: TDF tablet 300mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF tablet
Description: TDF tablet 300mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir Tablet
Description: Entecavir tablet 0.5mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir Tablet
Description: Entecavir tablet 0.5mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL-007
Description: QL-007 tablets 200mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL-007
Description: QL-007 tablets 200mg BID
Study: NCT02780947

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventricular tachycardia substrate ablation
Description: Study protocol~1. Baseline programmed ventricular stimulation performed from the LV~2. High density endocardial LV mapping using CARTO® 3 System~3. Randomized substrate ablation in half patients. Ablation end-point is considered the elimination of all endocardial late and early potentials (LPs and EPs)~4. Final programmed ventricular stimulation performed from the LV~Programmed ventricular stimulation with up to 4 extrastimuli from LV is performed and repeated at the end of the procedure in patients undergoing substrate ablation.
Study: NCT00275275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Requip PR
Description: Requip 24-Hour once a day for one month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Requip PR
Description: Requip 24-Hour once a day for one month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Requip PR
Description: Requip 24-Hour once a day for one month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirapex
Description: All subjects started the study on Mirapex. They were all then switched to Requip PR based on a conversion factor of 1:3, 1:4 or 1:5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirapex
Description: All subjects started the study on Mirapex. They were all then switched to Requip PR based on a conversion factor of 1:3, 1:4 or 1:5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirapex
Description: All subjects started the study on Mirapex. They were all then switched to Requip PR based on a conversion factor of 1:3, 1:4 or 1:5.
Study: NCT00003531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Stage IV Pancreatic Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT03753776

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pills of Radium bromatum
Description: Placebo pills of Radium bromatum will be taken since 48h before radiotherapy and until 15 days after the end of radiation, or until grade 2 or higher radiodermatitis apparition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium bromatum pills
Description: Homeopathic Radium bromatum pills will be taken since 48h before radiotherapy and until 15 days after the end of radiation, or until grade 2 or higher radiodermatitis apparition

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Radium bromatum/Apis mellifica/Belladonna placebo pills
Description: Placebo pills of Radium bromatum, Apis mellifica and Belladonna will be taken since grade 2 or higher radiodermatitis and until 15 days after the end of radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium bromatum/Apis mellifica/Belladonna pills
Description: Pills of Radium bromatum, Apis mellifica and Belladonna will be taken since grade 2 or higher radiodermatitis and until 15 days after the end of radiation
Study: NCT02917252

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3-hydroxybuturate
Description: Drink of ketone bodies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drink of saline
Study: NCT03211039

Intervention type: GENETIC
Group type: OTHER
Intervention: Genomic sequencing and molecular diagnostic results, if any.
Description: Patients and their families will be randomized to either receive whole genome sequencing or whole exome sequencing.

Intervention type: GENETIC
Group type: OTHER
Intervention: Genomic sequencing and molecular diagnostic results, if any.
Description: Patients and their families will be randomized to either receive whole genome sequencing or whole exome sequencing.
Study: NCT03993327

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Iodine I 124 Monoclonal Antibody M5A
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan
Study: NCT02222038

Intervention type: OTHER
Group type: OTHER
Intervention: skin biopsy
Study: NCT02159391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interview
Description: The Brief Motivational Interview implies an empathic interviewing style which (i) recognizes, examines and tries to resolve the patient´s ambivalence to facilitate behavioral change, (ii) promotes self-efficacy, (iii) allows flexibility in strategies, including short-term aims to reduce consumption and decrease damage linked to this consumption (like road accidents), (iv) works to reduce the patient's resistances, and (v) provides individualized feedback, if deemed appropriate, to promote recognition of the problem and cognitive restructuring.